Logo image of VIRX

VIRACTA THERAPEUTICS INC (VIRX) Stock Fundamental Analysis

NASDAQ:VIRX - Nasdaq - US92765F1084 - Common Stock - Currency: USD

0.0778  -0.07 (-48.65%)

After market: 0.071 -0.01 (-8.74%)

Fundamental Rating

0

Overall VIRX gets a fundamental rating of 0 out of 10. We evaluated VIRX against 557 industry peers in the Biotechnology industry. Both the profitability and financial health of VIRX have multiple concerns. VIRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VIRX has reported negative net income.
In the past year VIRX has reported a negative cash flow from operations.
In the past 5 years VIRX always reported negative net income.
VIRX had a negative operating cash flow in each of the past 5 years.
VIRX Yearly Net Income VS EBIT VS OCF VS FCFVIRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

VIRX has a worse Return On Assets (-197.14%) than 90.27% of its industry peers.
Industry RankSector Rank
ROA -197.14%
ROE N/A
ROIC N/A
ROA(3y)-82.33%
ROA(5y)-80.57%
ROE(3y)-160.27%
ROE(5y)-134.85%
ROIC(3y)N/A
ROIC(5y)N/A
VIRX Yearly ROA, ROE, ROICVIRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VIRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VIRX Yearly Profit, Operating, Gross MarginsVIRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, VIRX has more shares outstanding
VIRX has more shares outstanding than it did 5 years ago.
VIRX has a worse debt/assets ratio than last year.
VIRX Yearly Shares OutstandingVIRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
VIRX Yearly Total Debt VS Total AssetsVIRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -26.24, we must say that VIRX is in the distress zone and has some risk of bankruptcy.
VIRX has a worse Altman-Z score (-26.24) than 89.91% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.24
ROIC/WACCN/A
WACCN/A
VIRX Yearly LT Debt VS Equity VS FCFVIRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.76 indicates that VIRX may have some problems paying its short term obligations.
VIRX has a Current ratio of 0.76. This is amonst the worse of the industry: VIRX underperforms 91.33% of its industry peers.
VIRX has a Quick Ratio of 0.76. This is a bad value and indicates that VIRX is not financially healthy enough and could expect problems in meeting its short term obligations.
VIRX has a Quick ratio of 0.76. This is amonst the worse of the industry: VIRX underperforms 91.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.76
VIRX Yearly Current Assets VS Current LiabilitesVIRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

VIRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.29%, which is quite good.
EPS 1Y (TTM)11.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VIRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.18%
EPS Next 2Y31.22%
EPS Next 3Y19.14%
EPS Next 5Y14.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIRX Yearly Revenue VS EstimatesVIRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2027 2028 2029 2030 2031 50M 100M 150M 200M
VIRX Yearly EPS VS EstimatesVIRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIRX. In the last year negative earnings were reported.
Also next year VIRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIRX Price Earnings VS Forward Price EarningsVIRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIRX Per share dataVIRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as VIRX's earnings are expected to grow with 19.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.22%
EPS Next 3Y19.14%

More info and screens

0

5. Dividend

5.1 Amount

VIRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRACTA THERAPEUTICS INC

NASDAQ:VIRX (2/3/2025, 8:01:34 PM)

After market: 0.071 -0.01 (-8.74%)

0.0778

-0.07 (-48.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-05 2025-03-05/amc
Inst Owners48.83%
Inst Owner Change-94.68%
Ins Owners2.41%
Ins Owner Change0%
Market Cap3.09M
Analysts43.33
Price Target3.06 (3833.16%)
Short Float %0.06%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.86%
Min EPS beat(2)-8.04%
Max EPS beat(2)33.76%
EPS beat(4)2
Avg EPS beat(4)12.76%
Min EPS beat(4)-10.69%
Max EPS beat(4)36.03%
EPS beat(8)3
Avg EPS beat(8)8.46%
EPS beat(12)6
Avg EPS beat(12)5.61%
EPS beat(16)8
Avg EPS beat(16)20.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)33.33%
EPS NQ rev (3m)56.18%
EPS NY rev (1m)0%
EPS NY rev (3m)8.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -197.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.33%
ROA(5y)-80.57%
ROE(3y)-160.27%
ROE(5y)-134.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.76
Altman-Z -26.24
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)63.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y38.18%
EPS Next 2Y31.22%
EPS Next 3Y19.14%
EPS Next 5Y14.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.09%
OCF growth 3YN/A
OCF growth 5YN/A